Heiner Dreismann Joins Sense as Chairman

3rd August 2018, Oxford, UK and Cambridge, UK.  Sense Biodetection Limited (Sense) has today announced the appointment of Heiner Dreismann as non-executive Chairman. Heiner was previously the President and CEO of Roche Molecular Systems, the world leader in molecular diagnostics.

During his tenure at Roche Molecular Systems, Heiner oversaw the substantial growth of the PCR business with revenues doubling in five years. In his earlier career at Roche, Heiner led the integration office of the successful acquisition of Boehringer Mannheim into Roche Diagnostics and went on to become Head of Global Business Development with responsibility for the entire diagnostics business.

Commenting on his appointment Heiner said:

“I am delighted to join Sense at this exciting stage in its development and to be in a position to help the company achieve its ambitious plans. Sense has a compelling proposition and a significant opportunity to transform the IVD field with a new class of molecular diagnostic product.”

Sense CEO Harry Lamble commented:

“I am very pleased to welcome Heiner to Sense. I regard Heiner as a pioneer of the molecular diagnostics industry and the whole team is thrilled to have the endorsement of such a global leader in the field. His market insight and wealth of experience will bring great value to the company as we realise our vision of developing the next generation of truly point-of-care molecular tests.”

Heiner has over 35 years experience in the leadership of high growth businesses on a global basis. Since leaving Roche he has served on the board of a number of private and public biotech and healthcare companies.

About Sense: Sense Biodetection Limited is a molecular diagnostics company focused on bringing tests to the True Point-of-CareTM to improve healthcare decisions and patient outcomes. Sense is developing a new class of diagnostic product to break down the barriers that have led to the current model of centralised testing. Sense products are simple, ultra-rapid, handheld tests which remove the need for advanced hardware to determine a result.  Sense operates from bespoke laboratory, development and manufacturing facilities in Oxford and Cambridge, UK and is growing rapidly as it seeks to take its first product to market.


For Heiner’s full profile please click here

To open a PDF of this press release click here

Contact for Media Enquiries: info@sense-bio.com